abstract |
The present invention relates to novel imidazolidine derivatives of the formula (I), in which B, E, W, Y, R, R<2>, R<3>, R<30>, e and h have the meanings given in the claims. The compounds of the formula (I) are valuable pharmaceutical active compounds which are suitable, for example, for treating inflammatory disease, for example rheumatoid arthritis, or allergic diseases. The compounds of the formula (I) are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role. The invention furthermore relates to processes for preparing the compounds of the formula (I), to their use and to pharmaceutical preparations which comprise compounds of the formula (I). |